LifeStance Health Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LFST research report →
Range $9 – $19
Price Chart
About the company
LifeStance Health Group, Inc. specializes in delivering outpatient mental healthcare services through its subsidiary network. The company offers a comprehensive array of mental health solutions, encompassing psychiatric evaluations and treatment, specialized psychological and neuropsychological testing, and diverse therapeutic modalities including individual, family, and group therapy sessions.
- CEO
- David Patrick Bourdon
- IPO
- 2021
- Employees
- 8,863
- HQ
- Scottsdale, AZ, US
Get TickerSpark's AI analysis on LFST
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.25B
- P/E
- 72.66
- Fwd P/E
- 69.54
- PEG
- 0.03
- P/S
- 3.13
- P/B
- 3.53
- EV/EBITDA
- 35.34
- Div Yield
- 0.00%
- Gross Margin
- 34.39%
- Op Margin
- 6.21%
- Net Margin
- 4.29%
- ROE
- 4.82%
- ROIC
- 4.23%
Latest fiscal year · YoY change
- Revenue
- $1.42B+13.9%
- Gross Profit
- $461.10M+14.6%
- Op Income
- $24.15M
- Net Income
- $9.66M+116.8%
- EPS
- $0.03+120.0%
- OCF Growth
- +36.3%
- FCF Growth
- +28.4%
- 52W High
- $15.66
- 52W Low
- $6.09
- 50D MA
- $12.88
- 200D MA
- $9.81
- Beta
- 1.30
- RSI (14)
- 48
- Avg Volume
- 5.23M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
LifeStance delivered another strong quarter with 25% revenue growth, 15% adjusted EBITDA margin, and an increased full-year outlook, while flagging a temporary 2027 EHR headwind.· November 5, 2026
- Revenue grew 25% to $456 million, with visits up 17% to 2.7 million and total revenue per visit up 7% to $170.
- Adjusted EBITDA rose 70% to $68 million, with a 15% margin for the second straight quarter.
- LifeStance raised full-year guidance across revenue, center margin, and adjusted EBITDA, and now expects 2024-like margin expansion to continue.
- Clinician count reached 8,863, up 11%, after adding 321 clinicians in the quarter; management said recruiting remains strong and retention stable.
- Management said 2027 growth will be temporarily pressured by the new EHR, with an estimated 1 to 2 percentage point hit to revenue growth, but expects margins to keep expanding after implementation.
Third-quarter revenue was $456 million, up 25% year over year. Visit volumes were 2.7 million, up 17%, and total revenue per visit was $170, up 7%. Center margin was $161 million, up 38%, and adjusted EBITDA was $68 million, up 70%, with a 15% margin. Net income was $22 million, up $21 million versus Q3 last year, and free cash flow was $22 million versus $17 million a year ago. The company ended the quarter with $219 million of cash and $256 million of net long-term debt; net leverage was 0.2x and gross leverage was 1.2x, after $25 million of share repurchases. Full-year guidance was raised to revenue of $1.741 billion to $1.761 billion, center margin of $599 million to $613 million, and adjusted EBITDA of $242 million to $250 million. Fourth-quarter guidance is revenue of $446 million to $466 million, center margin of $149 million to $163 million, and adjusted EBITDA of $56 million to $64 million. For 2027, management expects revenue growth toward the lower end of its long-term mid-teens range because of the EHR rollout, with the EHR expected to affect revenue growth by about 1 to 2 percentage points.
Dave Bourdon struck a highly positive tone, calling the quarter “tremendous” and highlighting momentum across the business. He emphasized continued clinician growth, strong productivity, a growing specialty-services footprint, and disciplined expansion through de novos and tuck-in M&A. He also framed the EHR transition as a manageable, phased rollout that should ultimately improve access, efficiency, and long-term growth.
Ryan McGroarty focused on the operating leverage in the quarter and the raised outlook. He cited $456 million of revenue, $68 million of adjusted EBITDA, 15% margin, $219 million of cash, and net leverage of 0.2x, while noting the balance sheet remained strong after $25 million in repurchases. He also said the company will reinvest some of the year’s upside in the second half, expects stock-based compensation of about $60 million to $70 million this year, and estimated the EHR implementation will cost roughly $20 million to $30 million, either through adjusted EBITDA or capitalization.
Analysts pressed on specialty services, asking what could slow the ramp and whether better outcomes could improve payer reimbursement. Management said rollout is deliberately paced in clusters of 3 to 5 centers, with about a handful of TMS/Spravato sites added per quarter, and that outcomes should help payer discussions and reimbursement. Questions also focused on the EHR rollout, margin sustainability, and 2027 growth timing; management said the implementation will be phased through 2027 with no carryover into 2028, and reiterated that margins should continue expanding long term despite the temporary revenue growth hit.
The bull case is that demand, clinician recruiting, and pricing momentum all remain strong, allowing LifeStance to keep posting 25%+ revenue growth and 15% EBITDA margins. Specialty services are still early, but management sees room to expand them, improve payer coverage, and grow faster than the core business.
The main risk flagged on the call is the new EHR rollout, which management said will temporarily reduce 2027 revenue growth by 1 to 2 percentage points and require $20 million to $30 million of implementation costs. Management also acknowledged that specialty services still face payer variability and adoption hurdles, and that the full benefits of newer therapies like psilocybin are too early to quantify.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 52.4%
- Shares Outstanding
- 380.19M
- Float Shares
- 199.03M
of shares held by institutions
300 13F filers
Buy/sell ratio 0.40. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tpg Gp A, LLC | 79.69M | ▼ 32.05M |
| Fmr LLC | 59.46M | ▲ 1.21M |
| Blackrock, Inc. | 40.76M | ▲ 4.41M |
| Vanguard Group Inc | 17.70M | ▲ 3.09M |
| Vanguard Portfolio Management LLC | 17.47M | ▲ 3.50M |
| Summit Partners L P | 16.62M | ▼ 6.69M |
| Vanguard Capital Management LLC | 11.38M | ▲ 1.64M |
| Price T Rowe Associates Inc | 10.05M | ▲ 7.28M |
| Marshall Wace, Llp | 9.96M | ▲ 8.33M |
| State Street Corp | 9.89M | ▲ 1.66M |
| Jennison Associates LLC | 8.71M | ▼ 3.37M |
| Dimensional Fund Advisors LP | 8.43M | ▼ 3.00M |
Held by 450 ETFs
Biggest fund positions in LFST by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Burdick Kenneth A | sell | 124,228 |
| Nov 12, 26 | Burdick Kenneth A | other | 2,999,997 |
| Nov 12, 26 | Burdick Kenneth A | other | 2,148,328 |
| Nov 12, 26 | Burdick Kenneth A | sell | 159,624 |
| Nov 12, 26 | Burdick Kenneth A | other | 2,999,997 |
| Nov 12, 26 | TPG GP A, LLC | sell | 37,233,110 |
| Nov 10, 26 | Pardo Ryan | sell | 587,920 |
| Nov 10, 26 | Pardo Ryan | sell | 2,216,585 |
| Nov 10, 26 | Miller Lisa K | other | 14,722 |
| Nov 11, 26 | Miller Lisa K | sell | 14,663 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LFST coverage
Recent articles, reports, and earnings notes.
No research on LFST yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LFST report →Does LifeStance Health (LFST) Have the Potential to Rally 25.94% as Wall Street Analysts Expect?
zacks.com · Nov 20
Healthcare Stocks Overtake Tech: 5 Strong Buys Combining Growth And Value
seekingalpha.com · Nov 17
Surging Earnings Estimates Signal Upside for LifeStance Health (LFST) Stock
zacks.com · Nov 9
LifeStance Health Group Announces Pricing of Secondary Public Offering
globenewswire.com · Nov 9
LifeStance Health Group Announces Launch of Secondary Public Offering
globenewswire.com · Nov 9
What Makes LifeStance Health Group (LFST) a Strong Momentum Stock: Buy Now?
zacks.com · Nov 6
LifeStance Health Group, Inc. (LFST) Hits Fresh High: Is There Still Room to Run?
zacks.com · Nov 6
What LifeStance Health Group (LFST) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.